Russian coronavirus vaccine passes early tests: report

Published September 5, 2020
Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite that was the first launched into space in 1957, had already received approval. —  AP/File
Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite that was the first launched into space in 1957, had already received approval. — AP/File

LONDON: Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with “no serious adverse events”, according to research published in The Lancet on Friday, but experts said the trials were too small to prove safety and effectiveness.

Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite that was the first launched into space in 1957, had already received approval.

This raised concerns among Western scientists over a lack of safety data, with some warning that moving too quickly on a vaccine could be dangerous. Russia denounced criticism as an attempt to undermine Moscow’s research.

In the Lancet study, Russian researchers reported on two small trials, each involving 38 healthy adults aged between 18 and 60, who were given a two-part immunisation.

Each participant was given a dose of the first part of the vaccine and then given a booster with the second part 21 days later. They were monitored over 42 days and all developed antibodies within the first three weeks.

The report said the data showed that the vaccine was “safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers”.

The trials were open label and not randomised, meaning there was no placebo and the participants knew they were receiving the vaccine and were not randomly assigned to different treatment groups.

Researchers underlined that larger and longer trials — including a placebo comparison — would be needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection.

The report said the 76 participants of these trials would be monitored up to 180 days, adding that a more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers “from different age and risk groups”.

Naor Bar-Zeev of Johns Hopkins Bloomberg School of Public Health, who was not involved in the study, said the research was “encouraging but small”, adding that it did not give any data on effectiveness among older age groups, who are particularly vulnerable to Covid-19.

“Showing safety will be crucial with Covid-19 vaccines, not only for vaccine acceptance but also for trust in vaccination broadly,” he said in a commentary in the Lancet.

“Since vaccines are given to healthy people and, during the Covid-19 pandemic, potentially to everyone after approval following phase 3 trials, safety is paramount.”

The pandemic has seen an unprecedented mobilisation of funding and research to rush through a vaccine that can protect billions of people worldwide.

This week the US urged states to get ready for a potential Covid-19 vaccine rollout two days before the presidential election in November, sparking concerns President Donald Trump’s administration is accelerating research to fit a political timetable.

Russia has said that industrial production of its version is expected from September.

Published in Dawn, September 5th, 2020

Opinion

Poisoning minds
23 Jan 2021

Poisoning minds

ICS cadets were raised on James Mill’s notorious work.
The fog of Broadsheet
23 Jan 2021

The fog of Broadsheet

How can the government pump credibility into an official probe when it has already declared its own political verdict?
Cheating on online exams
23 Jan 2021

Cheating on online exams

The difficulty of preventing online cheating and low ethical standards means that these days most students cheat.
Language mess
Updated 22 Jan 2021

Language mess

Our policy confuses the medium-of-instruction debate with the language-acquisition debate.

Editorial

23 Jan 2021

Power price hike

ALREADY struggling to cope with the impact of the Covid-19 pandemic and rising food prices, consumers received yet...
Updated 23 Jan 2021

Israeli land grab

WITH the chapter now closed on the Trump presidency, the eyes of many in the international community — ...
23 Jan 2021

New PhD policy

EARLIER in the week, the HEC chairman announced several changes for undergraduate and PhD degrees in the country....
Updated 22 Jan 2021

Time to heal

A multitude of foreign issues will test Biden’s mettle and require progressive thinking.
22 Jan 2021

Foreign funding

AS the pressure builds on his party in the foreign funding case, Prime Minister Imran Khan has called for an ...
22 Jan 2021

Decaying PTV

THE Cabinet Committee on State-Owned Enterprises has decided to remove Pakistan Television from the list of...